Axial Biotherapeutics

OverviewSuggest Edit

Axial Biotherapeutics is the latest microbiome firm to emerge. Private and venture capital investors, including Longwood Fund and Domain Associates, have put an initial $19 million into the California start-up.

Axial is based on the work of California Institute of Technology professor Sarkis Mazmanian. In mouse models, his lab has shown a connection between neurological disorders and interventions in the gut microbiome. Axial intends to expand on these discoveries to find pathways and mechanisms amenable to biotherapeutic intervention. Initial disease targets include autism and Parkinson’s disease.

Technology that Axial has licensed from Caltech includes Mazmanian’s work involving Bacteroides fragiles. Raising the level of these gut bacteria can reduce autism-like behavior in engineered mice.

HQWaltham, US

Key People/Management at Axial Biotherapeutics

Eric de la Fortelle

Eric de la Fortelle

Scott C. Brun

Scott C. Brun

David H. Donabedian

David H. Donabedian

Co-Founder, CEO and Director
Gregory T. Bates

Gregory T. Bates

Senior Vice President, Regulatory Affairs
Sarkis Mazmanian

Sarkis Mazmanian

Co-Founder and Director
A. Stewart Campbell

A. Stewart Campbell

SVP, Research & Development
Show more

Axial Biotherapeutics Office Locations

Axial Biotherapeutics has an office in Waltham
Waltham, US (HQ)
9 4th Ave
Show all (1)

Axial Biotherapeutics Financials and Metrics

Summary Metrics

Founding Date


Axial Biotherapeutics total Funding

$54.5 m

Axial Biotherapeutics latest funding size

$10 m

Time since last funding

a year ago

Axial Biotherapeutics investors

Axial Biotherapeutics's latest funding round in June 2019 was reported to be $10 m. In total, Axial Biotherapeutics has raised $54.5 m
Show all financial metrics

Axial Biotherapeutics Online and Social Media Presence

Embed Graph

Axial Biotherapeutics Blogs

Axial Biotherapeutics to Participate in 5 th Annual BMO Private Company Showcase

WALTHAM, Mass., October 11, 2019 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5 th Annual BMO Private Company Showca…

Axial Biotherapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis

$10M investment as Series B extension, bringing total amount raised to $35M Direct investment for the discovery of gut targeted, small molecule therapeutics in oncology utilizing Axial’s novel platform technology WALTHAM, Mass., June 20, 2019 – Axial Biotherapeutics, a biotechnology company dedicate…
Show more

Axial Biotherapeutics Frequently Asked Questions

  • When was Axial Biotherapeutics founded?

    Axial Biotherapeutics was founded in 2013.

  • Who are Axial Biotherapeutics key executives?

    Axial Biotherapeutics's key executives are Eric de la Fortelle, Scott C. Brun and David H. Donabedian.

  • Who are Axial Biotherapeutics competitors?

    Competitors of Axial Biotherapeutics include Odonate Therapeutics, Centrexion and Principia BioPharma.

  • Where is Axial Biotherapeutics headquarters?

    Axial Biotherapeutics headquarters is located at 9 4th Ave, Waltham.

  • Where are Axial Biotherapeutics offices?

    Axial Biotherapeutics has an office in Waltham.

  • How many offices does Axial Biotherapeutics have?

    Axial Biotherapeutics has 1 office.